Logo image of ARVN

ARVINAS INC (ARVN) Stock Overview

NASDAQ:ARVN - US04335A1051 - Common Stock

7.52 USD
+0.04 (+0.53%)
Last: 8/26/2025, 9:56:09 AM

ARVN Key Statistics, Chart & Performance

Key Statistics
52 Week High29.61
52 Week Low5.9
Market Cap552.12M
Shares73.42M
Float68.33M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.01
PEN/A
Fwd PEN/A
Earnings (Next)10-28 2025-10-28/bmo
IPO09-27 2018-09-27
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ARVN short term performance overview.The bars show the price performance of ARVN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

ARVN long term performance overview.The bars show the price performance of ARVN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ARVN is 7.52 USD. In the past month the price decreased by -1.71%. In the past year, price decreased by -71.41%.

ARVINAS INC / ARVN Daily stock chart

ARVN Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.06 688.73B
JNJ JOHNSON & JOHNSON 17.63 424.54B
AZN ASTRAZENECA PLC-SPONS ADR 17.98 247.45B
NVO NOVO-NORDISK A/S-SPONS ADR 14.09 244.83B
NVS NOVARTIS AG-SPONSORED ADR 14.22 243.70B
MRK MERCK & CO. INC. 11.07 212.91B
PFE PFIZER INC 7.43 143.13B
SNY SANOFI-ADR 11.4 123.44B
BMY BRISTOL-MYERS SQUIBB CO 7.01 96.03B
GSK GSK PLC-SPON ADR 8.79 80.29B
ZTS ZOETIS INC 25.01 68.95B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.53 46.93B

About ARVN

Company Profile

ARVN logo image Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 430 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Company Info

ARVINAS INC

5 Science Park

New Haven CONNECTICUT 06511 US

CEO: John Houston

Employees: 430

ARVN Company Website

ARVN Investor Relations

Phone: 12035351456

ARVINAS INC / ARVN FAQ

What is the stock price of ARVINAS INC today?

The current stock price of ARVN is 7.52 USD. The price increased by 0.53% in the last trading session.


What is the ticker symbol for ARVINAS INC stock?

The exchange symbol of ARVINAS INC is ARVN and it is listed on the Nasdaq exchange.


On which exchange is ARVN stock listed?

ARVN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARVINAS INC stock?

27 analysts have analysed ARVN and the average price target is 13.32 USD. This implies a price increase of 77.13% is expected in the next year compared to the current price of 7.52. Check the ARVINAS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARVINAS INC worth?

ARVINAS INC (ARVN) has a market capitalization of 552.12M USD. This makes ARVN a Small Cap stock.


How many employees does ARVINAS INC have?

ARVINAS INC (ARVN) currently has 430 employees.


What are the support and resistance levels for ARVINAS INC (ARVN) stock?

ARVINAS INC (ARVN) has a support level at 7.16 and a resistance level at 7.96. Check the full technical report for a detailed analysis of ARVN support and resistance levels.


Is ARVINAS INC (ARVN) expected to grow?

The Revenue of ARVINAS INC (ARVN) is expected to grow by 3.55% in the next year. Check the estimates tab for more information on the ARVN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARVINAS INC (ARVN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARVINAS INC (ARVN) stock pay dividends?

ARVN does not pay a dividend.


When does ARVINAS INC (ARVN) report earnings?

ARVINAS INC (ARVN) will report earnings on 2025-10-28, before the market open.


What is the Price/Earnings (PE) ratio of ARVINAS INC (ARVN)?

ARVINAS INC (ARVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.01).


What is the Short Interest ratio of ARVINAS INC (ARVN) stock?

The outstanding short interest for ARVINAS INC (ARVN) is 11.16% of its float. Check the ownership tab for more information on the ARVN short interest.


ARVN Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ARVN. When comparing the yearly performance of all stocks, ARVN is a bad performer in the overall market: 94.24% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ARVN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ARVN. ARVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARVN Financial Highlights

Over the last trailing twelve months ARVN reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 80.46% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.98%
ROE -11.92%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-71.43%
Sales Q2Q%-70.72%
EPS 1Y (TTM)80.46%
Revenue 1Y (TTM)73.48%

ARVN Forecast & Estimates

27 analysts have analysed ARVN and the average price target is 13.32 USD. This implies a price increase of 77.13% is expected in the next year compared to the current price of 7.52.

For the next year, analysts expect an EPS growth of 53.6% and a revenue growth 3.55% for ARVN


Analysts
Analysts77.04
Price Target13.32 (77.13%)
EPS Next Y53.6%
Revenue Next Year3.55%

ARVN Ownership

Ownership
Inst Owners90.93%
Ins Owners2.16%
Short Float %11.16%
Short Ratio3.75